{"entities":[{"id":"aib-doc-recursion-prospectus-2021","name":"Recursion Pharmaceuticals, Inc. IPO prospectus (424B4)","type":"document","subtype":"Prospectus","description":"SEC 424B4, prospectus dated 15 April 2021, filed 16 April 2021. The prospectus cover states \"Prospectus dated April 15, 2021\"; the EDGAR index gives the filing date 2021-04-16.","sourceIds":["source-aib-companies-rxrx-424b4"]}],"claims":[{"id":"aib-co-recursion-clinical-programs-2021","subject":"aib-doc-recursion-prospectus-2021","predicate":"states_provision","object":{"kind":"literal","value":"company statement: four clinical stage programs (April 2021)"},"topic":"institutions","statement":"Recursion's IPO prospectus (15 April 2021) states that the company had four clinical stage programs and 33 additional programs in preclinical development.","time":{"kind":"event","date":"2021-04-15","basis":"publication","note":"Prospectus date; the statement is a snapshot of the company's pipeline as it describes it."},"resolution":"supported","evidenceIds":["evidence-aib-co-recursion-clinical-programs-2021-1"],"attributes":{"provision":{"kind":"statement","key":"co-recursion-clinical-programs-2021"}}},{"id":"aib-co-recursion-ipo-2021","subject":"aib-doc-recursion-prospectus-2021","predicate":"states_provision","object":{"kind":"literal","value":"initial public offering: 24,242,424 Class A shares at $18.00; Nasdaq symbol RXRX"},"topic":"institutions","statement":"Recursion's prospectus dated 15 April 2021 states an initial public offering of 24,242,424 shares of Class A common stock at $18.00 per share, approved for listing on the Nasdaq Global Select Market under the symbol RXRX.","time":{"kind":"event","date":"2021-04-15","basis":"publication","note":"Prospectus date; the prospectus states delivery of shares on or about April 20, 2021. Trading and closing dates are not recorded here."},"resolution":"supported","evidenceIds":["evidence-aib-co-recursion-ipo-2021-1","evidence-aib-co-recursion-ipo-2021-2"],"attributes":{"provision":{"kind":"statement","key":"co-recursion-ipo-2021"}}},{"id":"aib-co-recursion-mission-2021","subject":"aib-doc-recursion-prospectus-2021","predicate":"states_provision","object":{"kind":"literal","value":"stated mission: \"Decode Biology to Radically Improve Lives\""},"topic":"institutions","statement":"The letter from Recursion's co-founder and CEO in its IPO prospectus (15 April 2021) states the company's mission as \"to Decode Biology to Radically Improve Lives\".","time":{"kind":"event","date":"2021-04-15","basis":"publication","note":"Prospectus date."},"resolution":"supported","evidenceIds":["evidence-aib-co-recursion-mission-2021-1"],"attributes":{"provision":{"kind":"statement","key":"co-recursion-mission-2021"}}},{"id":"aib-co-recursion-purpose-2021","subject":"aib-doc-recursion-prospectus-2021","predicate":"states_provision","object":{"kind":"literal","value":"self-description: \"decoding biology\" with the goal of \"industrializing drug discovery\"; Recursion OS and Recursion Map"},"topic":"institutions","statement":"Recursion's IPO prospectus (15 April 2021) describes the company as a clinical-stage biotechnology company decoding biology by integrating biology, chemistry, automation, data science and engineering, with the goal of \"industrializing drug discovery\", and names the Recursion OS, including the Recursion Map, which it describes as \"a suite of custom software, algorithms, and machine learning tools\", as central to that mission.","time":{"kind":"event","date":"2021-04-15","basis":"publication","note":"Prospectus date."},"resolution":"supported","evidenceIds":["evidence-aib-co-recursion-purpose-2021-1","evidence-aib-co-recursion-purpose-2021-2","evidence-aib-co-recursion-purpose-2021-3"],"attributes":{"provision":{"kind":"statement","key":"co-recursion-purpose-2021"}}}],"sources":[{"id":"source-aib-companies-rxrx-424b4","documentId":"aib-doc-recursion-prospectus-2021","title":"Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock","authors":["Recursion Pharmaceuticals, Inc. (filed with the US SEC)"],"publisher":"Recursion Pharmaceuticals, Inc. (filed with the US SEC)","publisherId":"aib-recursion","publicationDate":"2021-04-15","version":"Retrieved for the candidate pack on 2026-10-30 (SHA-256 487039a60194b9c022cbf378210cd78655434c824bb3d7ae49f77ed721d01b4a). SEC EDGAR 424B4, accession 0001193125-21-119404, filed 2021-04-16; prospectus dated April 15, 2021; as served on 2026-10-30.","evidenceUrl":"https://www.sec.gov/Archives/edgar/data/1601830/000119312521119404/d89478d424b4.htm","language":"en"}],"evidence":[{"id":"evidence-aib-co-recursion-clinical-programs-2021-1","claimId":"aib-co-recursion-clinical-programs-2021","sourceId":"source-aib-companies-rxrx-424b4","support":"supports","locator":"Risk factors","passage":"We have four clinical stage programs and 33 additional programs in various stages of preclinical development.","passageType":"quote"},{"id":"evidence-aib-co-recursion-ipo-2021-1","claimId":"aib-co-recursion-ipo-2021","sourceId":"source-aib-companies-rxrx-424b4","support":"supports","locator":"Prospectus cover","passage":"This is the initial public offering of shares of Class A common stock of Recursion Pharmaceuticals, Inc. We are offering 24,242,424 shares of our Class A common stock. The initial public offering price is $18.00 per share.","passageType":"quote"},{"id":"evidence-aib-co-recursion-mission-2021-1","claimId":"aib-co-recursion-mission-2021","sourceId":"source-aib-companies-rxrx-424b4","support":"supports","locator":"A Letter from our Co-Founder and CEO","passage":"Our mission is to Decode Biology to Radically Improve Lives.","passageType":"quote"},{"id":"evidence-aib-co-recursion-purpose-2021-1","claimId":"aib-co-recursion-purpose-2021","sourceId":"source-aib-companies-rxrx-424b4","support":"supports","locator":"Prospectus summary, \"Overview\"","passage":"We are a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.","passageType":"quote"}],"at":{"entities":[1364],"claims":[3535,3536,3537,3538],"sources":[1138],"evidence":[4866,4867,4869,4870]},"index":{"byClaim":[],"marks":[],"chronicle":{"years":[{"year":1863,"topics":{"ideas":5},"stated":0},{"year":1865,"topics":{"ideas":1},"stated":0},{"year":1872,"topics":{"ideas":7},"stated":0},{"year":1943,"topics":{"ideas":1},"stated":0},{"year":1947,"topics":{"ideas":2},"stated":0},{"year":1950,"topics":{"ideas":7},"stated":0},{"year":1951,"topics":{"ideas":5},"stated":0},{"year":1952,"topics":{"ideas":2},"stated":0},{"year":1955,"topics":{"ideas":31},"stated":0},{"year":1956,"topics":{"ideas":1},"stated":0},{"year":1957,"topics":{"ideas":1},"stated":0},{"year":1958,"topics":{"ideas":3},"stated":0},{"year":1959,"topics":{"ideas":6},"stated":0},{"year":1960,"topics":{"ideas":11},"stated":0},{"year":1961,"topics":{"ideas":10},"stated":0},{"year":1965,"topics":{"ideas":8},"stated":0},{"year":1966,"topics":{"ideas":20},"stated":0},{"year":1968,"topics":{"ideas":5},"stated":0},{"year":1969,"topics":{"ideas":2},"stated":0},{"year":1971,"topics":{"ideas":4},"stated":0},{"year":1972,"topics":{"ideas":1},"stated":0},{"year":1973,"topics":{"ideas":2},"stated":0},{"year":1974,"topics":{"ideas":2},"stated":0},{"year":1975,"topics":{"ideas":1},"stated":0},{"year":1976,"topics":{"ideas":1},"stated":0},{"year":1977,"topics":{"people":2,"ideas":8},"stated":0},{"year":1979,"topics":{"ideas":4},"stated":0},{"year":1980,"topics":{"ideas":2},"stated":0},{"year":1981,"topics":{"people":2},"stated":0},{"year":1982,"topics":{"ideas":4},"stated":0},{"year":1983,"topics":{"ideas":4},"stated":0},{"year":1984,"topics":{"ideas":21},"stated":0},{"year":1985,"topics":{"ideas":9},"stated":0},{"year":1986,"topics":{"ideas":18},"stated":0},{"year":1987,"topics":{"ideas":1},"stated":0},{"year":1988,"topics":{"ideas":6},"stated":0},{"year":1989,"topics":{"ideas":8},"stated":0},{"year":1990,"topics":{"ideas":5},"stated":0},{"year":1991,"topics":{"ideas":11},"stated":0},{"year":1992,"topics":{"ideas":9},"stated":0},{"year":1993,"topics":{"ideas":14,"people":3},"stated":0},{"year":1994,"topics":{"ideas":14},"stated":0},{"year":1995,"topics":{"ideas":10,"people":1},"stated":0},{"year":1996,"topics":{"ideas":71},"stated":0},{"year":1997,"topics":{"ideas":12},"stated":0},{"year":1998,"topics":{"ideas":49},"stated":0},{"year":1999,"topics":{"ideas":27,"people":1,"institutions":1},"stated":0},{"year":2000,"topics":{"ideas":62},"stated":0},{"year":2001,"topics":{"ideas":39},"stated":0},{"year":2002,"topics":{"ideas":30},"stated":0},{"year":2003,"topics":{"ideas":8},"stated":0},{"year":2004,"topics":{"ideas":12,"people":3},"stated":0},{"year":2005,"topics":{"ideas":10,"people":1},"stated":0},{"year":2006,"topics":{"ideas":26,"people":1},"stated":0},{"year":2007,"topics":{"ideas":20},"stated":0},{"year":2008,"topics":{"ideas":57,"people":3,"institutions":1},"stated":0},{"year":2009,"topics":{"ideas":10,"people":1},"stated":0},{"year":2010,"topics":{"people":3,"ideas":11,"institutions":1,"governance":4},"stated":0},{"year":2011,"topics":{"people":3,"ideas":7,"institutions":2},"stated":0},{"year":2012,"topics":{"people":4,"ideas":17,"institutions":2},"stated":0},{"year":2013,"topics":{"ideas":46,"people":4,"institutions":2,"capital":1},"stated":0},{"year":2014,"topics":{"institutions":2,"ideas":54,"people":5},"stated":0},{"year":2015,"topics":{"people":22,"ideas":122,"institutions":3,"capital":1},"stated":0},{"year":2016,"topics":{"ideas":88,"people":2},"stated":0},{"year":2017,"topics":{"people":16,"institutions":2,"ideas":128,"governance":2},"stated":0},{"year":2018,"topics":{"people":8,"ideas":158,"institutions":8,"governance":1},"stated":0},{"year":2019,"topics":{"capital":1,"compute":1,"people":10,"governance":19,"ideas":175,"institutions":4},"stated":0},{"year":2020,"topics":{"people":6,"ideas":98,"institutions":1,"governance":2},"stated":0},{"year":2021,"topics":{"people":27,"ideas":177,"compute":1,"institutions":23,"governance":4,"capital":6},"stated":0},{"year":2022,"topics":{"people":15,"ideas":217,"institutions":6,"governance":3,"compute":2,"capital":1},"stated":0},{"year":2023,"topics":{"capital":5,"compute":7,"institutions":23,"people":51,"governance":179,"ideas":389},"stated":0},{"year":2024,"topics":{"capital":12,"compute":19,"governance":282,"people":80,"ideas":178,"institutions":28},"stated":1},{"year":2025,"topics":{"governance":547,"compute":69,"capital":34,"people":90,"institutions":18,"ideas":178},"stated":7},{"year":2026,"topics":{"governance":442,"capital":8,"compute":32,"institutions":21,"ideas":91,"people":107},"stated":19},{"year":2027,"topics":{},"stated":9},{"year":2028,"topics":{},"stated":6},{"year":2029,"topics":{},"stated":3},{"year":2030,"topics":{},"stated":3},{"year":2032,"topics":{},"stated":2},{"year":2035,"topics":{},"stated":2},{"year":2039,"topics":{},"stated":1},{"year":2042,"topics":{},"stated":1},{"year":2050,"topics":{},"stated":1}],"scheduled":[],"statedBy":[]},"collections":[{"target":{"kind":"propositions","id":"superintelligence"},"title":"Propositions about superintelligence, 1863–2022","claimIds":[],"records":[]},{"target":{"kind":"propositions","id":"risk-debate"},"title":"Arguments about catastrophic risk from advanced AI","claimIds":[],"records":[]},{"target":{"kind":"propositions","id":"yudkowsky-arguments"},"title":"Eliezer Yudkowsky’s arguments on common claims about AI, 1996–2026","claimIds":[],"records":[]},{"target":{"kind":"propositions","id":"economics-of-machine-intelligence"},"title":"Economics of machine intelligence","claimIds":[],"records":[]},{"target":{"kind":"propositions","id":"orbital-compute-arguments"},"title":"Arguments about compute in orbit","claimIds":[],"records":[]},{"target":{"kind":"propositions","id":"ai-bio-arguments"},"title":"Arguments about AI and biological risk","claimIds":[],"records":[]},{"target":{"kind":"propositions","id":"ai-in-science"},"title":"AI in science","claimIds":[],"records":[]},{"target":{"kind":"documents"},"title":"Frontier safety frameworks","claimIds":[]},{"target":{"kind":"compare","id":"frontier-safety-frameworks"},"title":"Compare frameworks","claimIds":[]},{"target":{"kind":"control","id":"openai"},"title":"OpenAI’s control structure, 2015–2026","claimIds":[]},{"target":{"kind":"control","id":"anthropic"},"title":"Anthropic’s control structure, 2021–2026","claimIds":[]},{"target":{"kind":"commitments"},"title":"External commitments and obligations","claimIds":[]},{"target":{"kind":"question","id":"frameworks-to-obligations"},"title":"Frameworks, commitments and legal obligations, 2023–2026","claimIds":[]},{"target":{"kind":"reading"},"title":"Founding and early leadership","claimIds":[]}]},"version":"131evrz"}